Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Gastric03: Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in HER2-expressing Gastric Cancer
NCT04379596Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2020
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 14
01
Overview
A Phase 2 trial of trastuzumab deruxtecan in gastric cancer (GC), gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma (EAC), sponsored by AstraZeneca. Started Jun 2020; status: active, not recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT04379596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04379596.